Medpace Holdings (MEDP) Stock Price
Medpace Holdings Price
Over the last 12 years Medpace Holdings grew revenue by 20.4% annually, reaching 2.53 B USD. Earnings per share have grown at 26.2% per year over the last 12 years. For Medpace Holdings, the net margin of 17.8% is up versus 15.9% a few years ago. The consensus 12-month price target for Medpace Holdings is 610.00 USD, about 0.9% below where the stock trades today. Of 20 analysts, 7 rate the stock a buy — an overall Hold consensus.
Medpace Holdings stock price
Medpace Holdings business model & stock analysis
Frequently asked questions about Medpace Holdings
Medpace Holdings Inc is a clinical contract research organization (CRO) that provides services to pharmaceutical, biotechnology, and medical device companies. The company's business model revolves around offering comprehensive clinical trial management services, including protocol and study design, site selection and management, data management, and regulatory consulting. Medpace's CRO expertise enables efficient and successful execution of clinical trials in various therapeutic areas. With a focus on quality, accuracy, and compliance, Medpace is committed to facilitating the development of innovative pharmaceutical products to improve patient care.
Medpace Holdings Inc is primarily active in the contract research organization (CRO) industry. As a leading global CRO, Medpace provides various services to support the development of pharmaceutical, biotechnology, and medical device products. With its expertise in clinical research, regulatory affairs, and medical writing, Medpace assists companies in navigating the complex process of bringing new therapies to market. Additionally, Medpace works across a range of therapeutic areas, including cardiovascular, oncology, neurology, and infectious diseases. Through its comprehensive services and industry experience, Medpace contributes to advancements in healthcare by facilitating the efficient and innovative development of new medical treatments and therapies.
The main competitors of Medpace Holdings Inc in the market include PRA Health Sciences, ICON plc, and Syneos Health.
Medpace Holdings Inc. is a pharmaceutical contract research organization that provides comprehensive clinical research services to the biotechnology, pharmaceutical, and medical device industries. Founded in 1992 by Dr. August Troendle, Medpace has since grown to become a leading global player in the clinical research industry. With a focus on developing innovative and efficient drug development strategies, Medpace offers services ranging from site feasibility assessments to full-service clinical trial management. The company's team of experienced industry professionals and its commitment to quality and timeliness have propelled Medpace to great success in its mission to accelerate the development of safe and effective medical therapies.
Medpace Holdings Inc, a leading clinical research organization, has achieved notable milestones. The company successfully completed its initial public offering (IPO) in August 2016, marking a significant milestone in its growth trajectory. Medpace has consistently demonstrated its commitment to quality and innovation, which led to its inclusion in the S&P SmallCap 600 Index in 2018. Furthermore, the company expanded its global footprint by establishing offices in Australia, Singapore, and South Korea. Medpace's dedication to advancing medical research and providing exceptional services has earned it recognition as a top CRO (Contract Research Organization) by industry publications.
Medpace Holdings Inc is primarily present in various countries and regions worldwide. With a global presence, Medpace operates in North America, Europe, Asia-Pacific, and other emerging markets. The company has established offices and clinical research sites in numerous countries, including the United States, Canada, France, Germany, Belgium, the Netherlands, India, China, Japan, Singapore, and Australia. Being a leading clinical contract research organization, Medpace collaborates with pharmaceutical, biotechnology, and medical device companies across these regions to provide high-quality clinical research services.
Medpace Holdings Inc represents a strong commitment to quality, integrity, and innovation in the clinical research industry. As a leading global contract research organization (CRO), Medpace is dedicated to providing high-quality, comprehensive services to pharmaceutical and biotechnology companies. The company follows a customer-centric approach and strives to exceed expectations by delivering customized solutions tailored to each client's needs. Medpace emphasizes collaboration, transparency, and scientific excellence in its operations, fostering partnerships with clients and prioritizing the advancement of medical breakthroughs. With its robust corporate philosophy, Medpace continues to drive advancements in drug development and shape the future of clinical research.
Analysts currently set an average price target of 606.38 USD for the Medpace Holdings stock (median: 610.00 USD), implying -1.5 % versus the latest price. The consensus is based on 20 analyst ratings.
20 analysts currently rate the Medpace Holdings stock: 7 recommend buying, 12 holding and 1 selling. For 2026, analysts expect Medpace Holdings to generate revenue of 2.85 B USD and earnings per share of 17.12 USD.
Converted at the current exchange rate, the Medpace Holdings share trades at 549.11 EUR (615.42 USD).
The Medpace Holdings share (MEDP) is listed on 4 stock exchanges, including: NASDAQ (MEDP), Frankfurt (01P), München (01P.MU), Düsseldorf (01P.DU).
Medpace Holdings Inc. is a leading company in the clinical research industry. The company offers a wide range of clinical study services to its customers in the pharmaceutical, biotechnology, and medical device industries. The company is headquartered in Cincinnati, Ohio, USA and has more than 4,500 employees in 47 countries worldwide. Medpace operates its business through three segments: 1. Medpace Clinical Pharmacology Services (MCPS) 2. Medpace Research Operations (MRO) 3. Medpace Medical Device Division (MDD) Medpace Clinical Pharmacology Services (MCPS) is responsible for conducting phase I studies, which aim to test the safety and tolerability of new drugs, vaccines, or other therapies. Small groups of healthy volunteers are studied in a clinical setting to collect data that can later be used in advanced studies to evaluate the effectiveness of a product. Medpace Research Operations (MRO) covers a broader range of clinical studies, such as phase II, phase III, and post-marketing studies. The focus here is to assess the effectiveness and safety of drugs or medical devices in a larger number of patients. Medpace Medical Device Division (MDD) offers a wide range of services for evaluating the safety and effectiveness of medical devices and implants. The company employs a group of experienced experts who help in the development and conduct of clinical studies involving medical devices and implants. Medpace also offers its customers a variety of supportive services, such as data management, biostatistics, and medical monitoring. The company has also developed its own electronic data management platform, which provides a high level of efficiency and accuracy in conducting clinical studies. It is worth mentioning that Medpace does not offer products in the traditional sense. Instead, the services offered are supportive services for conducting clinical studies. However, Medpace is an important partner for leading pharmaceutical and medical companies worldwide, benefiting from Medpace's professional and excellent planning and execution of clinical studies. Medpace's business model is based on providing high-quality clinical study services that help its customers bring innovative therapies and medications to the market. Medpace is in a key position in the global clinical research industry and can rely on a strong market position and experienced team of experts.
The expected revenue of Medpace Holdings is 2.85 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Medpace Holdings is 495.97 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Medpace Holdings is currently 35.94. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Medpace Holdings stock.
The price-to-sales ratio (P/S) of Medpace Holdings is currently 6.25. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Medpace Holdings stock.
The Eulerpool Quality Score for Medpace Holdings is 7/10.
The ISIN of Medpace Holdings is US58506Q1094. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Medpace Holdings is A2APTV. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Medpace Holdings is MEDP. The ticker symbol is used to trade Medpace Holdings shares on the stock exchange.
Medpace Holdings stock
Medpace Holdings Peer Group
Medpace Holdings Ticker
Medpace Holdings FIGI
All fundamentals and in-depth analysis of Medpace Holdings
Our stock analysis for Medpace Holdings stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Medpace Holdings. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.